Novo plots $191M expansion at Danish plant

Novo Nordisk plans to invest almost 1 billion Danish kroner ($191 million) in a new biologics manufacturing facility in Kalundborg, Denmark that will manufacture biopharmaceuticals such as Factor VIIa, used in Novo's NovoSeven drug for hemophilia, as well as other biologic medicines. Reports

Suggested Articles

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.